SA
Log In
PHAT
OverviewIntelligenceChart
Signal
Bearish Setup2↓
Price
1↓
Move↓-2.14%Negative session
Volume
1→
Volume→0.6× avgNormal activity
Technical
1↓
RSI↓RSI 45Momentum negative
PRICE
Prev Close
12.87
Open
12.87
Day Range12.21 – 12.95
12.21
12.95
52W Range2.21 – 18.31
2.21
18.31
65% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-6.0x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.61
High vol
Performance
1D
-2.14%
5D
+9.90%
1M
+11.96%
3M
+1.49%
6M
-5.16%
YTD↓
-24.08%
1Y↑
+388.18%
Best: 1Y (+388.18%)Worst: YTD (-24.08%)
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +150% YoY · 85% gross margin
Valuation
FAIR
P/E not available
Health
WEAK
CR 2.2 · FCF negative
Lean Bullish
Key MetricsTTM
Market Cap$1.00B
Revenue TTM$204.89M
Net Income TTM-$157.30M
Free Cash Flow-$97.40M
Gross Margin84.9%
Net Margin-76.8%
Operating Margin-47.1%
Return on Equity39.2%
Return on Assets-51.6%
Debt / Equity-0.01
Current Ratio2.21
EPS TTM$-1.92
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
4 strong2 concern
62/100
Liquidity
2.21Strong
Leverage
-0.01Strong
Coverage
-1.5xConcern
ROE
39.2%Strong
ROIC
-53.4%Concern
Cash
$130MStrong
ANALYST COVERAGE9 analysts
BUY
▲ +122.3%upside to target
L $18.00
Med $28.00consensus
H $28.00
Buy
889%
Hold
111%
8 Buy (89%)1 Hold (11%)0 Sell (0%)
Full report →
Stock Health
Composite Score
2 of 5 signals bullish
3/10
Technicals
●
RSI RangeRSI 45 — Bearish momentum
✗
Volume
●
Volume FlowDistribution — institutional selling
✗
Fundamentals
●
Last EarningsMissed estimates
✗
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 2.21 — healthy liquidity
✓
Upcoming Events
EEarnings Report · Before OpenMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentAug 6, 2026
In 92 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBEARISH
Technicals →

Trend

▲ UptrendGolden Cross · 50D leads 200D by 3.0%

+3.0% vs SMA 50 · +6.1% vs SMA 200

Momentum

RSI44.8
Momentum fading
MACD-0.30
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$18.31+45.4%
Current
$12.60
EMA 50
$12.06-4.2%
EMA 200
$11.88-5.7%
52W Low
$2.21-82.5%
52-Week RangeMid-range
$2.2165th %ile$18.31
Squeeze SetupVolume-based
Distribution Pressure

Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.

20-Day Money Flow
Acc days:0
Dist days:0
Edge:Even
Volume Context
Avg Vol (50D)2.6M
Recent Vol (5D)
953K-64%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 7 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$174.5M
$168.7M–$188.5M
—-$3.16—
±7%
Moderate4
FY2026(current)
$334.0M
$332.1M–$335.9M
▲ +91.4%-$0.54—
±7%
High6
FY2027
$540.0M
$528.9M–$561.1M
▲ +61.6%$1.20—
±7%
High7
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryPHAT
Last 8Q
+3.5%avg beat
Beat 4 of 8 quartersMissed 4↑ Estimates rising
-4%
Q3'24
+16%
Q4'24
+39%
Q1'25
-1%
Q2'25
-4%
Q3'25
+50%
Q4'25
+50%
Q1'26
-118%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
Neutral — mixed activity
90d▲ 1▼ 0
BarclaysNeutral → Overweight
Mar 27
UPGRADE
Evercore ISIOutperform
May 11
UPGRADE
Goldman SachsSell
May 11
DOWNGRADE
JMP SecuritiesPerform
May 11
DOWNGRADE
Piper SandlerNeutral
May 11
DOWNGRADE
BTIGSell
May 11
DOWNGRADE
William BlairMarket Perform
May 11
DOWNGRADE
RBC CapitalOutperform
May 11
UPGRADE
Wells FargoEqual-Weight
May 11
UPGRADE
Insider Activity
SEC Filings →
3 Buys/3 SellsNeutral
Breedlove Robert Ch…Principal Acco…
$7K
Nov 3
SELL
Breedlove Robert Ch…Principal Acco…
$6K
Sep 5
SELL
Breedlove Robert Ch…Principal Acco…
$14K
Jul 16
SELL
Topper James NDir
$15K
May 21
BUY
Topper James NDir
$21K
May 14
BUY
Topper James NDir
$4K
May 13
BUY
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
Medicxi Ventures Management (Jersey) Ltd
7.5M—
2
WASATCH ADVISORS LP
1.3M▲
3
Simplify Asset Management Inc.
262K▼
4
Nuveen, LLC
117K▲
5
Stratos Wealth Partners, LTD.
100K▲
6
COMMONWEALTH EQUITY SERVICES, LLC
32K▲
7
INSPIRION WEALTH ADVISORS, LLC
20K▲
8
PROFUND ADVISORS LLC
16K▲
News & Activity

PHAT News

20 articles · 4h ago

About

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.

Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
Website
www.phathompharma.com ↗
Bill ApreaSenior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer
Jonathan BentleySenior Vice President and Head of Sales, Operations & Training
Nancy R. PhelanSenior Vice President of Marketing & Analytics
Peers— Health Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt Cap↓P/ERev GrwMarginELO
PHAT◀
$12.60-2.14%$1.0B—+21693.0%-12634.7%1500
BBIO
$68.78-0.30%$13.3B—+12626.1%-14525.8%1500
GH
$89.52-1.81%$11.7B—+3288.2%-4239.0%1500
MDGL
$502.47-3.12%$11.5B—+43205.3%-3008.0%1500
AXSM
$223.06-0.29%$11.4B—+6554.5%-2868.8%1500
ARWR
$74.93-1.91%$10.5B51.9+2325815.3%-19.7%1500
ENSG
$175.95-3.34%$10.3B28.0+1871.5%680.1%1500
Sector avg—-1.84%—39.9+345007.7%-5230.8%1500

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance